A nationwide shortage of the gold-standard bladder cancer drug BCG has many patients nervous. CP3 Affiliated Faculty member Dr. Benjamin Davies told the Washington Post that the price of BCG is "too low" and that a price increase could increase competition in manufacturing of the drug.